Global Corporates at BioTrinity in 2014

BioTrinity 2014 saw more senior business development involvement from Global Pharma and even more involvement from Corporate Venture funds with an ever great number of the key players being represented from both their BD&L and investment sides principally attending to look for in-licensing M&A and investment opportunities.

BioTrinity 2014 stats:

  • 80 global pharma/corporate venture delegates
  • 33 global pharma/medical technology corporates

See below for all Global Corporates who attended in 2014:

  • AbbVie (Director, Venture Investments)

  • Actelion Pharmaceutical (Executive Vice President & Chief Business Development Officer)

  • Amgen (Life Sciences Corporate Specialist)

  • Astellas Pharma Europe (Vice President, Business & Commercial Development)

  • AstraZeneca (Head of Personalized Healthcare, Corporate Development & Ventures)

  • AstraZeneca (VP Business Development Operations)

  • AstraZeneca (Search and Evaluation (Oncology))

  • AstraZeneca (Strategy and Externalisation Director)

  • AstraZeneca (Business Develpment Director)

  • Boehringer Ingelheim Venture Fund GmbH (Vice President)

  • Boehringer Ingelheim Venture Fund GmbH (Investment Manager/Director)

  • Boehringer Ingelheim Venture Fund GmbH (Investment Manager)

  • Boehringer Ingelheim Venture Fund GmbH (Investment Manager)

  • Bristol-Myers Squibb 

     

    (VP, Business Development)

  • Bristol-Myers Squibb (Head of Europe, Search & Evaluation)

  • Bristol-Myers Squibb 

    (VP, Search & Evaluation - Global)

  • Chiesi (New Business Development Manager)

  • Eli Lilly (CSO Neurodegenerative Diseases DHT)

  • Eli Lilly (Managing Director, Global External R&D Europe & Middle East)

  • Ferrer Internacional, SA (Licensing In Manager)

  • Genzyme Therapeutics (Director)

  • GSK (VP Business Development)

  • Inventages Venture Capital (UK) (Principal)

  • Inventages

     Venture Capital (UK)

     (Investment Manager)

  • Johnson & Johnson 

    (Head, J&J Innovation)

  • Johnson & Johnson (Senior Director, New Ventures)

  • Johnson & Johnson (Senior Director, New Ventures)

  • Johnson & Johnson (Director, Business Operations and Project Management)

  • Johnson & Johnson (Finance Director)

  • Johnson & Johnson (Platform Innovation & Incubator Strategy Leader)

  • Johnson & Johnson Development Corporation (USA) (VP Venture Investing)

  • Life Technologies (President & COO)

  • Linde AG (Head of Innovation & Development, Linde Healthcare)

  • Lundbeckfond Ventures (Denmark) (Partner)

  • Lundbeckfond Ventures (Denmark) (Senior Partner)

  • MedImmune Ventures (USA) (Managing Director)

  • MSD (USA) (Executive Director, Head of Strategy Licensing & Acquisitions)

  • MSD (UK) (Director, Business Development & Licensing MRL)

  • MRL Venture Fund (USA) (Managing Director)

  • Mitsui & Co. Global Investment (Venture Partner)

  • MorphoSys AG (Vice President, Corporate Finance & Corporate Development)

  • MorphoSys AG (Senior Director, Corporate Finance & Corporate Development)

  • MP Healthcare Venture Management (USA) (Vice President)

  • MP Healthcare Venture Management (USA) (Senior Manager)

  • Nordic Pharma (Special Projects Director)

  • Nordic Pharma (General Manager)

  • Norgine (Vice President)

  • Norgine (Director, Business Development)

  • Norgine Ventures (UK) (Head of Venture Investments)

  • Novartis Oncology (Director Global Strategic Alliances)

  • Novartis Venture Funds (Switzerland) (Partner)

  • Novo A/S (Denmark) (Partner)

  • Novo Nordisk (Denmark) (Innvation Sourcing Director)

  • Novo Seeds (Denmark) (Investment Director)

  • Pfizer (UK) (Head, Strategic Research Partnerships, Epigenetics)
  • Qiagen (VP Companion Diagnostic Partnership)

  • QuantumMDx (Group CEO)

  • Roche  (Head of External Drug Discovery)

  • Sanofi-Aventis Research & Development (France) (Director R&D Transactions)
  • Sanofi-Pasteur MSD (Head, Business Development)

  • Shire (Director

     of Business Development)

  • Shire (

    Global 

    Head of Business Development)

  • Shire (Director, Scientific Licensing)

  • SR One (UK) (Partner)

  • SR One (UK) (Partner)

  • Takeda Pharmaceuticals Europe (VP, Search & Evaluation, Global Business Development)

  • Takeda Pharmaceuticals Europe (Senior Director, Search & Evaluation)

  • Takeda Pharmaceuticals Europe (VP, New Frontier Sciences)

  • Takeda Ventures (USA) (President & CEO)

  • Unilever Ventures (Director)

  • Vertex Pharmaceuticals (Vice President, Biology)

  • Vertex Pharmaceuticals (Senior Program Manager)

 

See the Global Corporates who attended BioTrinity in 2013

 

 





BioTrinity 2014 highlights
1,014 delegates from 32 countries
624 companies
184 speakers
107 company showcase presentations
2,462 one-to-one meetings
130+ investor delegates from 12 countries
61 exhibitors
80 global pharma/corporate venture delegates
33 global pharma/medical technology corporates